Ecological time-series analysisModerate (ecological design)2014

States with Medical Marijuana Laws Had 25% Fewer Opioid Deaths

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.

Bachhuber, Marcus A; Saloner, Brendan; Cunningham, Chinazo O; Barry, Colleen L·JAMA Internal Medicine·PubMed

States with medical cannabis laws had 24.8% lower opioid overdose mortality — but a later follow-up through 2017 found the association disappeared, suggesting the relationship is more complex than simple substitution.

Between 1999 and 2010, prescription opioid overdose deaths in the United States more than quadrupled. By the end of the decade, opioids were killing more Americans than car accidents. The medical establishment that had created the crisis — prescribing opioids aggressively for chronic pain on the basis of pharmaceutical industry assurances that turned out to be catastrophically wrong — was scrambling for solutions.

Into this landscape, Marcus Bachhuber published a finding that made policymakers sit up: states that had legalized medical marijuana were seeing fewer opioid deaths. Not just a little fewer. Nearly 25% fewer.

The implication was enormous and immediately controversial. Could legal access to cannabis — a less dangerous pain treatment — be saving lives by reducing opioid use at the population level?

The Analysis

Bachhuber's team used death certificate data from all 50 states over twelve years (1999-2010), comparing opioid overdose mortality rates in states with and without medical cannabis laws. The analysis controlled for state-level differences using fixed effects models, incorporated opioid-related policies (prescription drug monitoring programs, pain clinic laws, state medical examiner requirements), and adjusted for unemployment rates.

24.8%

lower mean annual opioid overdose mortality rate in states with medical cannabis laws compared to states without — after controlling for state and year fixed effects, opioid policies, and economic conditions (95% CI: -37.5% to -9.5%, p = 0.003).

The association strengthened over time: -19.9% in the first year of implementation, growing to -33.3% by year six. This temporal pattern suggests a cumulative effect — as dispensaries opened, as patients gained access, as substitution patterns took hold, the opioid death reduction deepened.

Bachhuber et al. (2014), JAMA Intern Med 174(10):1668-1673

The trajectory was striking. The longer a state had medical cannabis laws, the larger the reduction in opioid deaths. This dose-response relationship in time — not just "states with laws had fewer deaths" but "the effect grew stronger the longer the laws were in effect" — was the single most persuasive element of the analysis.

What This Study Can and Cannot Tell Us

The Shover follow-up deserves attention. When researchers extended Bachhuber's analysis through 2017, the protective association disappeared — and in some models reversed. This doesn't necessarily invalidate the original finding. The opioid crisis changed fundamentally between 2010 and 2017: the dominant opioid shifted from prescription pills (which cannabis might plausibly replace for pain) to illicit fentanyl (which is driven by addiction, not pain management). The substitution hypothesis may only apply to the prescription opioid phase of the crisis.

The Policy Impact

Regardless of whether the causal mechanism is proven, Bachhuber's study had outsized influence on cannabis policy. It was cited in:

State legislative debates on medical cannabis
Congressional hearings on cannabis rescheduling
Public health arguments for harm reduction
Media coverage linking cannabis access to opioid crisis solutions

The finding gave cannabis advocates a powerful talking point: legalization saves lives. It gave policymakers a utilitarian argument beyond individual patient benefit: population-level harm reduction.

Frequently Asked Questions

The original 2014 analysis found a 24.8% lower opioid overdose mortality rate in states with medical cannabis laws, and the effect deepened over time. However, a 2019 follow-up extending the data through 2017 found the association disappeared and potentially reversed. The relationship appears more complex than a simple substitution effect and may depend on which phase of the opioid crisis is examined (prescription opioids vs. illicit fentanyl). The individual-level evidence for patients substituting cannabis for opioids is more consistent than the state-level ecological data.

For some patients, partially. Studies consistently show that patients with access to cannabis reduce their opioid use. But the clinical trial evidence shows cannabis provides modest pain relief — it's not a one-to-one replacement for opioids in severe pain. Cannabis is best understood as one tool in a comprehensive pain management strategy that may allow lower opioid doses, not as a complete opioid alternative.

The opioid crisis changed fundamentally after 2010. In the early period, deaths were primarily from prescription opioids prescribed for pain — a population where cannabis substitution is plausible. After 2010, deaths increasingly involved illicit heroin and fentanyl, driven by addiction rather than pain management. Cannabis is less likely to substitute for substances driven by addiction physiology than for prescriptions driven by pain treatment choices.

Cite this study

Bachhuber, Marcus A; Saloner, Brendan; Cunningham, Chinazo O; Barry, Colleen L. (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.. JAMA Internal Medicine, 174(10), 1668-1673. https://doi.org/10.1001/jamainternmed.2014.4005

View on PubMed

More from these researchers

Bachhuber, Marcus A(1)Saloner, Brendan(1)Cunningham, Chinazo O(3)